Explore more about: Diabetes

Researchers have established an RNA-based method that drives cells in the body to produce therapeutic proteins and secrete them into the bloodstream. The approach could extend the lifespan of drugs in the body, reducing the burden on patients.

Diabetic wounds are slow-healing, potentially life-threatening complications with limited treatment options. But a two-step, nanomaterial-based strategy may open doors to better care.

The qualities of flowing blood, or hemodynamics, hold important insights into vascular diseases, but technological limitations have largely kept measurements of these properties out of reach in the clinic. Now, there may be a potential solution on the horizon.

Frequent insulin injections are an unpleasant reality for many patients with type 1 diabetes. However, new technology could create a different reality for these patients.

Researchers at Carnegie Mellon University are developing lipid nanoparticles that are designed to carry mRNA specifically to the pancreas. Their study in mice could pave the way for novel therapies for intractable pancreatic diseases, such as diabetes and cancer.

In a new study published in Science Translational Medicine, researchers demonstrated that human kidney organoids are useful models to identify the point of permanent and reversible kidney cell damage and they also discovered a drug candidate that could potentially prevent chronic disease before reaching that point. Read more at STAT.

NIBIB-funded researchers are developing a robotic pill that, after swallowing, can deliver biologic drugs into the stomach, which could provide an alternative method for self-injection for a wide range of therapies.

The human body can be genetically inclined to attack its own cells, destroying the beta cells in the pancreas that make insulin, which helps convert sugar into energy. Called Type 1 diabetes, this disorder can occur at any age and can be fatal if not carefully managed with insulin shots or an insulin pump to balance the body's sugar levels.

A Rice University bioengineer and her Brown School of Engineering team were awarded an NIH grant to create gene activity sensors and activators that hold unmatched potential for the treatment of infectious diseases, diabetes, genetic disorders, and cancer. Source: AZO Life Sciences

NIBIB-funded engineers have developed a flexible epidermal patch that can simultaneously and continuously monitor cardiac output and metabolic levels of glucose, lactate, caffeine, or alcohol. The patch is a major step towards continuous non-invasive health monitoring.